Insights and News Library

Discover our Latest Thinking

Explore CenExel’s collection of insights from our expert team of scientists and leaders to help inform your strategy in today’s rapidly changing environment.

Fact Sheet

Shorten the Path of Life-Changing Therapies

Learn More


Analgesia Clinical Trials – What you should know but probably don’t

Learn More

Fact Sheet

Benefit from a Preferred Partnership

Learn More

Fact Sheet

Accelerate Early Phase Decisions

Learn More

Fact Sheet

Biomarkers in Early Phase Clinical Trials

Learn More

Fact Sheet

Drive Value from
Dynamic Vaccine Clinical Trial Execution

Learn More

Validation of a suite of ERP and QEEG biomarkers

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers   Written by: M. Cecchi a,*, M. Adachi b, A. Basile c, D.L. Buhl d, H. Chadchankar e, S. Christensen f, E. Christian g,...

Electrophysiology Based Biomarkers as Outcome Measures

Electrophysiology Based Biomarkers as Outcome Measures, Demonstrate Signal Detection and Reliability in a Simulated Clinical Trial at an Experienced Clinical Research Center Evaluating Study Drug (Ketamine) and Placebo Larry Ereshefsky1, Marco Cecchi2, Elan Cohen3, K....

FDA Approves ABRYSVO for RSV

In the last week, the FDA approved the first maternal vaccine designed to safeguard infants from respiratory syncytial virus (RSV) during the critical period immediately from birth up to 6 months of age, when they are most vulnerable to infection. RSV, a highly...

Placebo and Nocebo Response Mitigation

Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo effects within central nervous system and internal medicine clinical trials and developing...

CenExel FCR Wins Best of the Best

Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People's Choice, Best of the Best in Clinical Research. This remarkable achievement showcases CenExel FCR's unwavering dedication to advancing medical knowledge and...

Stuart Goldblatt Joins CenExel as CEO

Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of...

Training on the Placebo-Control Reminder Script

CenExel is proud to highlight the poster we're presenting at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2023, Miami, FL. ABSTRACT Introduction: Placebo and nocebo responses continue to hinder potential treatment effects...

Evaluation of mRNA-1273 Vaccine in Children

CenExel is proud to announce the publication of the work of Kimball A. Johnson, MD, from CenExel iResearch, in the New England Journal of Medicine. Dr. Johnson participated in a study of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. Other contributors included Evan J. Anderson, MD, C. Buddy Creech, MD, MPH, Vlasimir Berthaud, MD, MPH, Arin Piramzadian, DO, et al., for the KidCOVE Study Froup*

Efficacy and safety of olorinab

CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel’s Clinical Sciences team, in the Neurogastroenterology & Mortility journal. Dr. English participated in a study of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome. Other contributors included Lin Chang, Brooks D. Cash, Anthony Lembo, David C. Kunkel, Brett English, Beatriz Lindstrom, Guibao Gu, Sharon Skare, Kye Gilder, Stewart Turner, Fabio Cataldi, Donald Lipkis, and Tack Jan. The study aimed to assess the efficacy and safety of olorinab (IBS-D) and constipation (IBS-C).